This roundtable event includes four leading heart failure specialists discussing recent data related to SGLT2 inhibitors in reducing CV risk, HF hospitalisations and mortality and morbidity in HFrEF irrespective of T2DM. The panel also look at ongoing studies including those for HFpEF and CKD outcomes.

This video is part of a series and can be viewed at https://cardiology.radcliffe-group-pre-prod.com/video-index/past-present-and-future-sglt2-inhibitors-cv-outcomes